115648-45-8

Upstream product

• 118-71-8 Maltol 
• 7439-89-6 iron 
• 7705-08-0 iron(III) chloride 
• 121714-78-1 iron(III) chloride hexahydrate 

Relevant academic research and scientific papers

NOVEL POLYMORPHIC FORM OF FERRIC MALTOL

The present application generally provides ferric maltol of formula I, and more particularly a crystalline form alfa of Ferric maltol, which is characterized by its PXRD pattern as illustrated herein. Corresponding methods for producing the ferric maltol disclosed herein are also provided.

METHODS FOR PRODUCING FERRIC MALTOL COMPOSITIONS FROM ELEMENTAL IRON

Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, andferric maltol compositions produced by these methods and their usesare described.

METHODS FOR PRODUCING FERRIC MALTOL COMPOSITIONS FROM LIGAND MODIFIED AND LIGAND COATED FERRIC HYDROXIDES

Methods for producing ferric maltol compositions, such as ferric trimaltol,are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.

Determination of composition and instability constants of maltol complexes with iron(III) ions

Complexation of maltol (MH) with Fe3+ ions in aqueous solutions was studied. The compositions of [FeMa]2+, [FeMa2] +, and [FeMa3] complexes were determined by the method of isomolar series, and their instability constants were calculated. The values of the latter were confirmed by the method of apparent deviation from the Bouger - Lambert - Beer law. An increase in the Ma:Fe3+ ratio from 1 to 3 decreases the instability constants of the complexes. The [FeMa3] complex can be considered as a basis for the antianemic drug with a prolonged effect.

A Potential Iron Pharmaceutical Composition for the Treatment of Iron-deficiency Anaemia. The Crystal and Molecular Structure of mer-Tris-(3-hydroxy-2-methyl-4H-pyran-4-onato)iron(III)

mer-Tris(3-hydroxy-2-methyl-4H-pyran-4-onato)iron(III) has potential use in the treatment of iron-deficiency anaemia.It displays the ideal properties that a new iron chelation complex must possess to be an effective treatment.These properties are discussed.The crystal and molecular structure of this complex has been determined from single-crystal X-ray diffraction data and refined by least squares to R=0.0649 for 2735 independent reflections.The compounds crystallizes in the monoclinic space group P21/c with cell dimensions a=7.369(1), b=14.720(3), and c=19.964(5) Angstroem, β=100.41(2) deg, Z=4.The iron atom lies in a distorted octahedral environment with the three ligands bonded through the hydroxy and ketone oxygen atoms to give the mer configuration.Variable-temperature 57Fe Moessbauer data for the complex are reported and the results are discussed in relation to the structure.